Moreover, recent survival analyses have showed that plasma phosphorylated tau (i.e. P-tau181 and P-tau217) and neurofilament light (NfL) could be effective biomarkers for separating MCI patients who converted to AD from those that did not40–42, though the AUCs were modest (P-tau181 = 0.77, NfL = 0.62)43. This evidence concerns the gene MAPT and Alzheimer disease.